FVIII concentrate

PreclinicalSmall molecule

TThe University of Texas Health Science Center, Houston

FVIII concentrate is one of 16 small molecule programs targeting Hemophilia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemophiliaActive, not recruiting

HemophiliaPreclinical

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Hemophilia

#DrugCompanyPhaseTrials

Videx

Bristol-Myers Squibb

Approved

1 2

Hivid

CConrado Roberto Hoffmann Filho

Approved

1 3

Epivir

GGlaxo Dba Glaxosmithkline

Approved

1 4

Zerit

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 5

Cyklokapron

JJ Molner

Approved

—6

Crixivan

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 7

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

4 8

Antithrombin Concentrate (ATIIIC)

Sanofi

Phase 3

2 9

Foscenvivint

KKiminori Kimura, MD

Phase 2

1 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Synovitis1 trial

Intensive Replacement Treatment in Haemophilia Patients With Synovitis

Completed·FFederico II University·Phase 4·NCT04784988·64 enrolled

Hemophilia A1 trial

Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia

Completed·TThe University of Texas Health Science Center, Houston··NCT01652027·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FVIII concentrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FVIII concentrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FVIII concentrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe University of Texas Health Science Center, Houston

FVIII concentrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Synovitis1 trial

Hemophilia A1 trial

References

Drug Info

Quick Facts

Related News